Pseudomonas aeruginosa Infections Global Clinical Trials Review, H1, 2018, a clinical trial report by GlobalData gives an overview of clinical trials scenario for Pseudomonas aeruginosa. It contains information regarding trial numbers, average enrolment in top countries, region-wise and country-wise (G7 & E7) trials coverage, trial phase, status and prominent drugs for in-progress trials. It also contains details of unaccomplished trials and trial enrolment trend seen in the last 5 years. Thus, giving a better understanding to the stakeholders regarding trial progresses, market opportunities and market growth.
Pseudomonas aeruginosa infections are bacterial infections caused by the ‘pseudomonas’ bacterium. The most common of these causing infections to humans is Pseudomonas aeruginosa. Also known as the drug-resistant superbug, these bacteria can prove to be severe- in many cases fatal- for a body with a weak immune system or diseased. Pseudomonas aeruginosa is generally acquired by patients who are already diseased and are in a hospital setting for more than a week, and hence they are also known as opportunistic bacteria. Known for its ubiquity, Pseudomonas aeruginosa can cause serious infections like cystic fibrosis or ventilator-associated pneumonia.
The healthcare industry has been facing a challenge to cure pseudomonas infections. Clinical trials are being performed worldwide to find more effective therapeutics for the same, as the earlier ones are proving to be ineffective. Multi-Drug Resistance or MDR as it is known is the resistance that the bacteria causing the disease develop towards the antibiotics, thus leading to the ineffectiveness of the drug. Pseudomonas aeruginosa in particular, have proved to be the most resilient one that exhibits high drug resistance mechanisms. Hence there is a high demand for research of new antibiotics to cure the same. Some of the other challenges faced in treatment are the resurfacing of the symptoms once the treatment is over or development of resistance mid-treatment regimen.
Research for development of new antibiotics and pseudomonas therapeutics are on a surge globally, with the USA being a dominant market in North America. Germany, France, and the UK are the top European countries investing in the research and trials. Experts believe that Asia is expected to become the focus of all the bio-medical and Pharma companies, with China, India, and Japan leading.
The global clinical trials market is on rising and with increasing global demand for effective drugs and therapies, the growth is anticipated to continue for the next decade. The main drivers of this potential growth will be technological advancements, globalization, diversity in medical profiles, population, economic developments, and favorable business regulations and policies. Apart from this, there is an increase in the funding and investments from private entities. A market shift might be the future, as companies are focusing on the emerging countries for their potential markets and business expansions. Also, the new- generation technologies are now helping the small and mid-size firms and research institutes to have access to technology, data and research platforms, that were earlier available to only the big players.
To Know More, Click On the link below:-
Ankur Gupta, Head Marketing & Communications